Based on disclosed results, revenue went from KRW 5.01 billion in 2022 to KRW 3.94 billion in 2023 (down 21.4% year on year) and KRW 3.93 billion in 2024 (down 0.3%), before jumping to KRW 9.23 billion in 2025 (up 134.9%). Among 2022 to 2025, 2025 was the largest year and 2024 the smallest.
Operating losses were KRW 24.5 billion in 2022, KRW 21.3 billion in 2023 (losses continued, with the loss narrowing), KRW 26.8 billion in 2024 (losses continued, with the loss widening), and KRW 25.6 billion in 2025 (losses continued, with the loss narrowing).
The company has been in the red for four consecutive years from 2022 through 2025. The operating margin moved from -488.2% in 2022 to -541.8% in 2023, -681.7% in 2024, and -277.4% in 2025. The 2025 improvement owed more to revenue more than doubling than to a sharp cut in the loss.
According to press reports, pharma division sales exceeded KRW 9 billion in 2025. Net loss attributable to shareholders was KRW 24.6 billion in 2022, KRW 20.4 billion in 2023, KRW 26.5 billion in 2024, and KRW 24.2 billion in 2025.
Net loss including non-controlling interests is disclosed at the same levels for each year. The debt ratio fell from 31.0% in 2022 and 33.9% in 2023 to 13.0% in 2024 and 6.1% in 2025. At the end of 2025, total equity was KRW 110.1 billion and total liabilities were KRW 6.69 billion.
Operating cash flow was -KRW 22.1 billion in 2022, -KRW 17 billion in 2023, -KRW 17.8 billion in 2024, and -KRW 22.5 billion in 2025, negative every year with the outflow widening in 2025.
Quarterly revenue was KRW 2.76 billion in the third quarter of 2025, KRW 2.91 billion in the fourth quarter (up 5.3% from the prior quarter), KRW 2.85 billion in the first quarter of 2026, KRW 2.24 billion in the second quarter (down 21.3% quarter on quarter), and KRW 3.1 billion in the third quarter of 2026 (up 38.0% quarter on quarter and 12.0% year on year).
The operating loss widened from KRW 6.14 billion in the third quarter of 2025 to KRW 8.16 billion in the fourth quarter, narrowed to KRW 5.65 billion in the first quarter of 2026, widened again to KRW 6.18 billion in the second quarter, and narrowed to KRW 3.85 billion in the third quarter of 2026.
Net loss attributable to shareholders was KRW 2.97 billion in the third quarter of 2026, with the loss narrowing from a year earlier, and totaled KRW 21.2 billion over the last four quarters.
Based on disclosed results, the company has posted losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.